Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Olga Yu. Li"'
Autor:
Vladimir I. Vorobyev, Eduard G. Gemdzhian, Liudmila V. Fedorova, Natalia B. Mikhailova, Ridvan K. Ilyasov, Liliia P. Kaleikina, Olga S. Trubyakova, Kamil D. Kaplanov, Elena V. Melnichenko, Elena V. Martynova, Elena P. Yakovleva, Olga Yu. Li, Elena V. Tarasenko, Elena P. Chumakova, Natalia B. Bulieva, Ekaterina S. Nesterova, Oleg V. Margolin, Vera A. Zherebtsova, Lev S. Butaev, Vadim V. Ptushkin
Publikováno v:
Терапевтический архив, Vol 93, Iss 7, Pp 770-777 (2021)
Background. Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current approaches have greatly improved patients outcomes, but relapse is inevitable. In phase IIIII clinical trials, ibrutinib has shown significant activi
Externí odkaz:
https://doaj.org/article/b83a79daf0fc4b7db69564adb35219aa
Autor:
Liudmila V. Fedorova, Elena V. Melnichenko, Kaplanov Kd, Elena V. Martynova, Vladimir I. Vorobyev, Natalia B. Mikhailova, Liliia P. Kaleikina, Natalia B. Bulieva, Olga S. Trubyakova, Elena P. Yakovleva, Elena P. Chumakova, Elena V. Tarasenko, Vadim V. Ptushkin, Olga Yu. Li, Lev S. Butaev, Ridvan K. Ilyasov, E S Nesterova, Vera A. Zherebtsova, Margolin Ov, Eduard G. Gemdzhian
Publikováno v:
Терапевтический архив, Vol 93, Iss 7, Pp 770-777 (2021)
Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current approaches have greatly improved patients outcomes, but relapse is inevitable. In phase IIIII clinical trials, ibrutinib has shown significant activity in patien
Autor:
Tatiana Shelekhova, Lyudmila Anchukova, Alexander Levanov, Oleg Rukavitsyn, Tatyana Ionova, Marina Demchenkova, Olga Vinogradova, Olga Yu. Li, K D Kaplanov, Anna Kopylova, Tatiana Kravchuk, Tatiana Mitina, Dolgorzhap Dasheeva, Lyudmila Ivanova, Tatiana Nikitina, Elena Rimashevskaya, Elena Babich, Natalia Porfirieva, Anna Zinkovskaya, Tatiana Esenina, Sergei Dubov, Polina Simashova, Svetlana Volkova, Elena Ado, Mariya Shirokova, Yulia Kochkareva, Natalia Saraeva, Marina Savinova
Publikováno v:
Blood. 136:28-29
The goal of treatment of relapsed/refractory multiple myeloma (RRMM) is to control the disease, prolong survival, reduce disease-related symptoms, and improve quality of life (QoL). Comprehensive evaluation of new treatment regimens in RRMM pts is wo
Publikováno v:
Вісник Харківського національного університету імені В.Н. Каразіна. Серія: Математичне моделювання, інформаційні технології, автоматизовані системи управління, Iss 46 (2020)
Externí odkaz:
https://doaj.org/article/b68728d3ce7148329f478fe4a3e05e41